Organogenesis Holdings Inc.

NasdaqCM:ORGO Rapport sur les actions

Capitalisation boursière : US$533.0m

Organogenesis Holdings Bilan de santé

Santé financière contrôle des critères 6/6

Organogenesis Holdings possède un total de capitaux propres de $278.5M et une dette totale de $62.1M, ce qui porte son ratio d'endettement à 22.3%. Son actif total et son passif total sont $446.3M et de $167.7M. L'EBIT de Organogenesis Holdings est $11.9M ce qui fait que son ratio de couverture des intérêts 5.7. Elle dispose de liquidités et de placements à court terme de $94.3M.

Informations clés

22.3%

Ratio d'endettement

US$62.12m

Dette

Ratio de couverture des intérêts5.7x
Argent liquideUS$94.34m
Fonds propresUS$278.55m
Total du passifUS$167.75m
Total des actifsUS$446.30m

Mises à jour récentes de la santé financière

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ORGO ( $238.5M ) dépassent ses passifs à court terme ( $77.3M ).

Passif à long terme: Les actifs à court terme de ORGO ( $238.5M ) dépassent ses passifs à long terme ( $90.5M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: ORGO dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de ORGO a été réduit de 648.7% à 22.3% au cours des 5 dernières années.

Couverture de la dette: La dette de ORGO est bien couverte par le flux de trésorerie opérationnel ( 22.4% ).

Couverture des intérêts: Les paiements d'intérêts de ORGO sur sa dette sont bien couverts par l'EBIT ( 5.7 x couverture).


Bilan


Découvrir des entreprises saines